

CADTH DRUG REIMBURSEMENT REVIEW

# Pharmacoeconomic Report

ISATUXIMAB (SARCLISA)

(Sanofi Genzyme)

**Indication:** In combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

## Table of Contents

List of Tables .....	4
Abbreviations .....	5
Executive Summary .....	6
Conclusions .....	8
Stakeholder Input Relevant to the Economic Review .....	9
Economic Review .....	10
Appendix 1: Cost Comparison Table .....	11
Appendix 2: Submission Quality .....	12
Appendix 3: Additional Information on the Submitted Economic Evaluation .....	13
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation .....	14
Appendix 5: Submitted BIA and CADTH Appraisal .....	15

## List of Tables

Table 1: Submitted for Review.....	6
Table 2: Summary of Economic Evaluation.....	7

## Abbreviations

<b>AIC</b>	Akaike information criterion
<b>AE</b>	adverse events
<b>BIC</b>	Bayesian information criterion
<b>CD-38</b>	cluster of differentiation 38 (cyclic ADP ribose hydrolase)
<b>CycloPd</b>	cyclophosphamide in combination with pomalidomide plus dexamethasone
<b>EQ-5D-5L</b>	Euroqol-5 dimension-5 level
<b>ICER</b>	incremental cost-effectiveness ratio
<b>IsaPd</b>	isatuximab in combination with pomalidomide plus dexamethasone
<b>Kd</b>	carfilzomib plus dexamethasone
<b>OS</b>	overall survival
<b>Pd</b>	pomalidomide plus dexamethasone
<b>PFS</b>	progression-free survival
<b>PSM</b>	partition-survival model
<b>QALY</b>	quality-adjusted life-years
<b>RDI</b>	relative dosing intensity
<b>RRMM</b>	relapsed and/or refractory multiple myeloma
<b>TTD</b>	time-to-treatment discontinuation
<b>WTP</b>	willingness to pay

## Executive Summary

The executive summary is comprised of two tables (Table 1: Background and Table 2: Economic Evaluation) and a conclusion.

**Table 1: Submitted for Review**

Item	Description
Drug product	Isatuximab (Sarclisa), solution for injection (20 mg/mL), 100 mg or 500 mg single-use vial
Submitted price	Isatuximab, 6 mL (100 mg / 5 mL), intravenous injection: \$757.90 Isatuximab, 30 mL (500 mg / 25 mL), intravenous injection: \$3,789.49
Indication	Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Health Canada approval status	NOC
Health Canada review pathway	Standard review
NOC date	April 29, 2020
Reimbursement request	As per indication
Sponsor	Sanofi-Aventis Canada Inc.
Submission history	Previously reviewed: No

mg – milligrams; mL = milliliters; NOC = Notice of Compliance.

**Table 2: Summary of Economic Evaluation**

Component	Description
<b>Type of economic evaluation</b>	Cost-utility analysis Partitioned survival model
<b>Target population</b>	Adult patients with relapse and/or refractory multiple myeloma who have received two or more prior therapies, including lenalidomide and a proteasome inhibitor
<b>Treatment</b>	Isatuximab in combination with pomalidomide + dexamethasone (IsaPd)
<b>Comparator</b>	Pomalidomide + dexamethasone (Pd)
<b>Perspective</b>	Canadian publicly funded health care payer
<b>Outcome</b>	Quality-adjusted life-years (QALYs)
<b>Time horizon</b>	Lifetime (20 years)
<b>Key data source</b>	ICARIA-MM trial
<b>Submitted results for base case</b>	ICER = \$170,541 per QALY (1.25 incremental QALYs and \$213,412 incremental costs)
<b>Key limitations</b>	<ul style="list-style-type: none"> <li>• Not all relevant comparators were included in the sponsor's base-case (i.e., cyclophosphamide, pomalidomide and dexamethasone; carfilzomib and dexamethasone).</li> <li>• Several issues were identified with the extrapolation of the clinical efficacy data within the submitted economic evaluation. As OS data was not mature, there was uncertainty regarding extrapolations beyond the trial period (13.9 months). Clinical experts noted that the sponsor's chosen OS and PFS curves were optimistic leading to overestimation of QALYs.</li> <li>• Health state utilities applied within the model lacked face validity and the inclusion of treatment-specific utilities in effect double-counted the disutility associated with adverse events.</li> <li>• Total drug acquisition costs of IsaPd and Pd may have been overestimated due to the sponsor's choice of the TTD parametric curve according to the clinical experts consulted on this review.</li> <li>• Subsequent therapies modelled in the sponsor's base case were not representative of Canadian clinical practice.</li> </ul>
<b>CADTH reanalysis results</b>	<ul style="list-style-type: none"> <li>• CADTH conducted a reanalysis which included: selecting the Weibull distribution for the OS of IsaPd and Pd; selecting the Gompertz distribution for PFS and TTD of IsaPd; selecting the Weibull distribution for PFS and TTD of Pd; and, revising the utility values for PFS and progressed disease health states.</li> <li>• Based on CADTH reanalyses, the ICER for IsaPd versus Pd is \$1,555,947 per QALY gained. At a price reduction of 99.9% for isatuximab, the ICER for IsaPd versus Pd is \$106,084 per QALY gained. There is no price reduction for isatuximab at which IsaPd can be considered cost-effective at a \$50,000 per QALY threshold, unless there were significant price reductions for pomalidomide. At a 98% price reduction for isatuximab combined with a 50% price reduction for pomalidomide, IsaPd is cost-effective within the \$50,000 per QALY threshold.</li> </ul>

ICER = incremental cost-effectiveness ratio; IsaPd = isatuximab in combination with pomalidomide plus dexamethasone; OS = overall survival; Pd = pomalidomide plus dexamethasone; PFS = progression-free survival; QALY= quality-adjusted life-year; TTD = time-to-discontinuation.

## Conclusions

Results from the ICARIA-MM trial, comparing IsaPd to Pd, was unable to demonstrate a statistically significant difference in mortality or clinically meaningful changes in HRQoL between treatment arms. Yet, the key drivers to the submitted economic model were the choice of parametric survival distributions for OS and the health-state utility values.

CADTH undertook reanalyses of the sponsor's economic model to address some of the identified limitations. CADTH's base case reanalysis included a more clinically plausible extrapolation for OS, PFS and TTD and revisions to the utility estimates. Based on CADTH reanalyses, the ICER for IsaPd versus Pd was \$1,555,947 per QALY gained. With a 99.9% price reduction for isatuximab alone, the ICER decreases to \$106,084 per QALY gained. Price reduction analyses suggest that, even if isatuximab was offered at zero cost, IsaPd would not be cost-effective at a \$50,000 per QALY threshold as the price of pomalidomide remains high. Only upon a 98% price reduction for isatuximab combined with a 50% price reduction for pomalidomide would IsaPd be considered cost-effective within the \$50,000 per QALY threshold.

The results were primarily driven by the increased acquisition cost of isatuximab and the incremental clinical benefit expected with isatuximab over the model's time horizon for IsaPd compared to Pd. A majority of the clinical benefits (61%) were observed in the extrapolation period, indicative that uncertainties in the extrapolation period remain key drivers. Many of these uncertainties could not be adequately addressed by CADTH (e.g., immature OS data, optimistic extrapolated PFS distributions that are not consistent with clinical experts' expectations). The CADTH reanalyses suggested a minor survival benefit of IsaPd relative to Pd (i.e., 0.22 additional life years). The cost-effectiveness of IsaPd compared to other relevant (and lower cost) comparator regimens such as Kd and CycloPd remains unknown at this time given the lack of evidence on its comparative effectiveness.

Based on the CADTH reanalyses, the budget impact from the introduction of isatuximab in combination with pomalidomide plus dexamethasone is expected to be \$30,974,282 in Year 1, \$24,653,555 in Year 2, \$19,982,110 in Year 3, for a total net budget impact of \$75,609,946 from the drug plan perspective.



## Stakeholder Input Relevant to the Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Appendix 1: Cost Comparison Table

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Appendix 2: Submission Quality

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## **Appendix 3: Additional Information on the Submitted Economic Evaluation**

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## **Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation**

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Appendix 5: Submitted BIA and CADTH Appraisal

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## References

1. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review sponsor submission: Sarclisa (isatuximab), 20 mg/mL concentrate for solution for infusion. Mississauga (ON): Sanofi Genzyme; 2020.
2. <sup>†</sup>Sarclisa™ (isatuximab for injection): concentrate for solution for infusion (20 mg/mL) [product monograph]. Laval (QC): Sanofi-Aventis Canada; 2020 Apr 29.
3. Clinical Study Report: EFC14335. A phase 3 randomized, open-label, multicenter study comparing isatuximab (SAR650984) in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma [internal sponsor's report]. Mississauga (ON): Sanofi Genzyme; 2019 Apr 4.
4. Exceptional Access Program: Drug Benefit Prices. Toronto (ON): Ministry of Health; Ministry of Long-term Care; 2020: [http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf\\_except\\_access.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx). Accessed 2020 Sep 21.
5. Ontario Ministry of Health Long-Term Care. Ontario drug benefit formulary/comparative drug index. 2020; <https://www.formulary.health.gov.on.ca/formulary/>. Accessed 2020 Sep 1.
6. Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. *J Palliat Care*. 2011;27(2):79-88.
7. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol*. 2016;17(1):27-38.
8. NICE. National Institute for Health and Care Excellence. Single Technology Appraisal Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [ID1477] Committee Papers. 2020.
9. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa (ON): CADTH; 2017: <https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition>. Accessed 2020 Sep 1.
10. Borg S, Nahi H, Hansson M, Lee D, Elvidge J, Persson U. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. *Acta Oncol*. 2016;55(5):554-560.
11. Pelligra CG, Parikh K, Guo S, et al. Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States. *Clin Ther*. 2017;39(10):1986-2005.e1985.
12. Generic submissions under review: about the Generic Submissions Under Review (GSUR) list. Ottawa (ON): Government of Canada; 2020: <https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/generic-submissions-under-review.html#wb-auto-4>. Accessed 2021 Jan 8.
13. Dexapoma regimen monograph. In: Cancer Care Ontario drug formulary: funded evidence-informed regimens. Toronto (ON): Cancer Care Ontario; 2020 Jun: <https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/46761>. Accessed 2020 Oct 28.
14. Carfdexa regimen monograph. In: Cancer Care Ontario drug formulary: funded evidence-informed regimens. Toronto (ON): Cancer Care Ontario; 2019 Sep: [https://www.cancercareontario.ca/sites/ccocancercare/files/CARFDEXA\\_HEM\\_MY.pdf](https://www.cancercareontario.ca/sites/ccocancercare/files/CARFDEXA_HEM_MY.pdf). Accessed 2020 Oct 28.
15. Cycldexapoma regimen monograph. In: Cancer Care Ontario drug formulary: funded evidence-informed regimens. Toronto (ON): Cancer Care Ontario; 2019 May: <https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/47786>. Accessed 2020 Oct 28.
16. Budget Impact Analysis [internal sponsor's report]. In: pan-Canadian Oncology Drug Review sponsor submission: Sarclisa (isatuximab), 20 mg/mL concentrate for solution for infusion. Mississauga (ON): Sanofi Genzyme; 2020.
17. Multiple myeloma market in Canada. MAT Mar 2020 update and trends. In: *ONCO-CAPPS oncology database*. North York (ON): Drug Intelligence; 2020.
18. Venner C, Bahlis N, Neri P, et al. In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort. *Blood*. 2015;126:4261-4261.
19. Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(6):781-794.